StrongIncrease
1,5-Anhydroglucitol
Tirzepatide → 1,5-Anhydroglucitol
Tirzepatide → 1,5-Anhydroglucitol
Evidence profile
StrongIncreaseGlycemic Control
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Tirzepatide improves glycemic control and weight loss sustainability in type 2 diabetes
Key finding
For tirzepatide-treated participants achieving HbA1c ≤48 mmol/mol (6.5%) at 52 weeks, 75–84% sustained this until study end.
This study analyzed the sustainability of glycemic control and weight loss with tirzepatide in type 2 diabetes patients, showing significant maintenance of HbA1c and weight loss.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Long-Term (1–5 y)
High bias
Last updated July 4, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Tirzepatide
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Primary outcome
HbA1c
Comparator
Insulin glargine once daily
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study analyzed the sustainability of glycemic control and weight loss with tirzepatide in type 2 diabetes patients, showing significant maintenance of HbA1c and weight loss.
Clinical relevance
These findings are significant for clinicians treating type 2 diabetes, as maintaining glycemic control and weight loss is crucial for reducing long-term complications. The sustained effects of tirzepatide may offer a valuable treatment option for patients struggling with diabetes management.
Keep in mind
Unclear effectiveness for some outcomes due to lack of detailed data. Results may not be generalizable beyond the study population. Limited information on long-term safety and efficacy.
Published in
Journal Reference
Publication details and source links for this paper.
Ewan RP, Stefano DP, Imre P, et al. Sustainability of Glycemic Control and Weight Loss with Tirzepatide in Type 2 Diabetes: A Post Hoc Analysis of the SURPASS-4 Trial. Diabetes. 2025;74(10):1850-1862. doi:10.2337/db25-0276
Save this study and add notes to your research library.
Main Effects
75–84% of tirzepatide-treated participants maintained HbA1c ≤48 mmol/mol (6.5%) until study end, with a decrease of -2.5 mmol/mol (p=0.001).
79–82% of participants who lost ≥10% of their weight at 52 weeks maintained this loss, with an average reduction of -5 kg (p=0.002).
Diabetes management self-efficacy scores improved significantly by 0.8 points (p=0.03).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide and 1,5-Anhydroglucitol, Body weight, Diabetes management self-efficacy, and 2 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
- 1,5-Anhydroglucitol
- Body weight
- Diabetes management self-efficacy
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
5
Evidence pairs
5
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
3
Related topics
5
Evidence pairs
291
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 5 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
StrongDecrease
Body weight
Tirzepatide → Body weight
Tirzepatide → Body weight
Evidence profile
StrongDecreaseWeight & Anthropometrics
Unlock full evidence details
StrongIncrease
Diabetes management self-efficacy
Tirzepatide → Diabetes management self-efficacy
Tirzepatide → Diabetes management self-efficacy
Evidence profile
StrongIncreasePatient-Reported
Unlock full evidence details
NoneNo Change
Gestational diabetes mellitus incidence
Tirzepatide → Gestational diabetes mellitus incidence
Tirzepatide → Gestational diabetes mellitus incidence
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
StrongDecrease
HbA1c
Tirzepatide → HbA1c
Tirzepatide → HbA1c
Evidence profile
StrongDecreaseGlycemic Control
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Tirzepatide led to a significant decrease in HbA1c levels by -2.5 mmol/mol.
- Participants experienced an average weight loss of -5 kg, maintained by 79–82%.
- Self-efficacy in diabetes management improved by 0.8 score.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Patients seeking effective weight management solutions.
Keep in Mind
- The study's findings are based on a specific trial population.
- Results may not apply to all demographics or diabetes types.
- Further research is needed to confirm long-term effects and safety.
Between the Lines
- Unclear effectiveness for some outcomes due to lack of detailed data.
- Results may not be generalizable beyond the study population.
- Limited information on long-term safety and efficacy.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
8 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
HbA1c Evidence Hub
All studies measuring HbA1c
8 studies
outcome_hubMeasures HbA1c as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
7 studies
outcome_hubMeasures Body Weight as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Tirzepatide and HbA1c
Intervention: TirzepatideOutcome: HbA1c
8 results
All studies on Tirzepatide and Body weight
Intervention: TirzepatideOutcome: Body weight
7 results
All studies on Tirzepatide
Intervention: Tirzepatide
8 results
All studies measuring HbA1c
Outcome: HbA1c
8 results
All studies measuring Body weight
Outcome: Body weight
7 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.5 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 23 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve HbA1c?
Strong Evidence
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.1 | strong positive | ConsensusScore™ Consistent | 1 study
Why this answer: This answer is based on 24 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve fasting glucose?
Strong Evidence
GLP-1 Receptor Agonists may improve Fasting Glucose.
ConsensusScore™: Results are generally consistent across studies.
Ranked evidence signals
- 1
1,5-Anhydroglucitol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on 7 supporting studies with generally consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve diabetes incidence and prevention?
Moderate Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Diabetes Incidence and Prevention.
ConsensusScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Gestational diabetes mellitus incidence
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a small number of supporting studies and should be interpreted cautiously.
Limitations
- Only a small number of supporting studies are available.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Newer diabetes drugs show stronger weight and blood sugar benefits in prediabetesTirzepatide improves glycemic control in early-onset type 2 diabetesTirzepatide enhances insulin sensitivity in type 2 diabetesSwitching to tirzepatide from dulaglutide improved HbA1c and weight across baseline characteristicsTirzepatide improves glycemic control and weight loss in type 2 diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.